Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Prof. John Chen
Mayo Clinic, Rochester, MN, USA
John Chen is a consultant and professor of ophthalmology and neurology, and neuro-ophthalmology fellowship director at the Mayo Clinic in Rochester, MN, USA.read more
Prof. Chen’s main interests are ophthalmic imaging, idiopathic intracranial hypertension and optic neuritis, especially NMOSD and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
Prof. Chen is a board member for the North American Neuro-Ophthalmology Society and is on multiple committees for the American Academy of Ophthalmology (AAO). He co-chairs the Upper Midwest Neuro-Ophthalmology Group, is a member of the American Ophthalmological Society and American Eye Study Club, and he previously served as the president for the Minnesota Academy of Ophthalmology.
He has over 200 peer-reviewed publications and has delivered over 200 oral presentations, including multiple named lectureships and visiting professorships.
Prof. John Chen Discloses: Consultancy fees from Horizon and UCB.
Prof. Friedemann Paul
Charité - Universitätsmedizin Berlin, Germany
Friedemann Paul is a professor at Charité – Universitätsmedizin Berlin, where he directs the Neuroimmunology Group and Multiple Sclerosis Research Center. He also serves as the head of the Experimental and Clinical Research Center (ECRC).read more
Prof. Paul is a renowned neurologist specializing in neuroimmunology. With a profound dedication to advancing medical research, Prof. Paul has made significant contributions to the understanding and treatment of multiple sclerosis and other neuroimmunological disorders. His extensive publication record, coupled with numerous awards and accolades, underscores his commitment to improving patient care and fostering innovation in neurology.
Prof. Friedemann Paul Discloses: Advisory board or panel fees from Alexion Pharma, Amgen, Biogen, Chugai Pharma, Förderpreis, Hexal, Horizon, Merck, Novartis, Novartis Pharma, Ridgeline Discovery, Roche, Sanofi, Teva GmbH and UCB. Consultancy fees from BioNTech, Bristol Myers Squibb, Hexal AG, Hoffmann-La Roche, MIAC AG, Roche Pharma and UCB Biopharma. Grants/research Support from Alexion, Amgen, Hexal (relationship terminated), Horizon, Novartis, Roche, Sanofi (relationship terminated) and UCB.
